LGR5 and endometrioid adenocarcinoma: SOX9+LGR5+ is the dominant signature in serous endometrial and some endometrioid adenocarcinomas and is positively associated with the ‘Copy-Number high’ molecular subtype from TCGA, as well as the clinically more aggressive stage III and IV adenocarcinomas.